Q32 Bio Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Q32 Bio Inc. (FIXX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$8.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- Q32 Bio Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$8.95M.
- Q32 Bio Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$7.61M.
- Q32 Bio Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $27.94M, a 43.31% decline year-over-year.
- Q32 Bio Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$7.39M.
- Q32 Bio Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was $29.82K.
- Q32 Bio Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$63.53K.
- Q32 Bio Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$53.74K.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.95M 10-Q · filed 2026-08-05 | -$16.55M 10-Q · filed 2026-08-05 | $11.38M derived: sum of 3 quarters · filed 2026-08-05 | $3.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$7.61M 10-Q · filed 2026-05-05 | $20.33M derived: sum of 2 quarters · filed 2026-05-05 | $12.94M derived: sum of 3 quarters · filed 2026-05-05 | $3.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $27.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $20.55M derived: sum of 2 quarters · filed 2026-03-10 | $11.06M derived: sum of 3 quarters · filed 2026-08-05 | $29.82K 10-K · filed 2026-03-10 |
| 2025-09-30 | -$7.39M 10-Q · filed 2025-11-13 | -$16.88M derived: sum of 2 quarters · filed 2026-08-05 | -$27.91M 10-Q · filed 2025-11-13 | $21.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$9.49M 10-Q · filed 2026-08-05 | -$20.52M 10-Q · filed 2026-08-05 | $28.76M derived: sum of 3 quarters · filed 2026-08-05 | $11.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$11.03M 10-Q · filed 2026-05-05 | $38.25M derived: sum of 2 quarters · filed 2026-05-05 | $20.65M derived: sum of 3 quarters · filed 2026-05-05 | $3.68M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $49.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $31.69M derived: sum of 2 quarters · filed 2026-03-10 | $14.71M derived: sum of 3 quarters · filed 2026-03-10 | -$63.53K 10-K · filed 2026-03-10 |
| 2024-09-30 | -$17.59M 10-Q · filed 2025-11-13 | -$34.57M derived: sum of 2 quarters · filed 2025-11-13 | -$49.34M 10-Q · filed 2025-11-13 | -$22.72M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$16.98M 10-Q · filed 2025-08-06 | -$31.75M 10-Q · filed 2025-08-06 | -$5.13M derived: sum of 3 quarters · filed 2025-08-06 | -$19.16M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$14.77M 10-Q · filed 2025-05-08 | $11.85M derived: sum of 2 quarters · filed 2025-05-08 | -$2.18M derived: sum of 3 quarters · filed 2025-05-08 | -$7.99M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $26.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $12.59M derived: sum of 2 quarters · filed 2025-03-11 | $6.78M derived: sum of 3 quarters · filed 2025-03-11 | -$53.74K 10-K · filed 2025-03-11 |
| 2023-09-30 | -$14.03M 10-Q · filed 2024-11-07 | -$19.84M derived: sum of 2 quarters · filed 2024-11-07 | -$26.68M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$5.81M 10-Q · filed 2024-08-08 | -$12.64M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$6.84M 10-Q · filed 2024-05-09 |